Glycopyrrolate inhalation - Chiesi

Drug Profile

Glycopyrrolate inhalation - Chiesi

Alternative Names: CHF-5259; Extrafine glycopyrronium bromide pMDI

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Chiesi
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 03 Sep 2016 Efficacy data from the phase II Trigon trial in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 01 Feb 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease (Treatment-experienced) in Czech Republic, Germany, Hungary (Inhalation) (NCT02680197)
  • 22 Jun 2015 Phase-II development for Chronic obstructive pulmonary disease is ongoing in Germany, Hungary, Italy, Poland and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top